Despite high P/E ratio and slower growth, investors hope for a business turnaround. However, if P/E aligns with recent growth rates, shareholders may face disappointment. Weak earnings and slower market growth suggest share price risk, posing significant risk to shareholders and potential investors.
With shrinking earnings and below market growth rates, it's hard to justify the high P/E ratio. Absent swift medium-term improvements, shares might drop and with it the P/E ratio. Current soaring prices may be risky, posing potential threats to investors.
博瑞醫葯股票討論區
$復星醫葯(600196.SH)$ $復星醫藥(02196.HK)$ $博瑞醫葯(688166.SH)$ $艾迪藥業(688488.SH)$
暫無評論